TP53 and ovarian serous adenocarcinoma: Particularly, we found out in our study that overexpression of ICAM-1, MXRA5, AURKA, and NEAT1 are associated with the activation of NPM1, Histone H3, and TP53 in patients with serous ovarian cancer who received the platinum–paclitaxel chemotherapy regimen.